Clinical trials: Myeloma-Multiple
Plasma Cell Myeloma
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and…
- Trial name
- IMROZ (NCT03319667)
- Testing
- Isatuximab SAR650984, Bortezomib, Lenalidomide
- Where
- 104 sites in United States, Australia and 19 more
- Volunteers
- 475 people
- Sponsor
- Sanofi
Relapse and/or Refractory Multiple Myeloma
A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)
The main aim of this study is to see how people with MM respond to previous or current treatment. Participants will be treated according to their clinic's standard practice.
- Trial name
- NCT04135963
- Where
- 8 sites in Portugal
- Volunteers
- 62 people
- Sponsor
- Takeda
Bone Neoplasms
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events…
- Trial name
- NCT00434447
- Testing
- Zoledronic acid
- Where
- 10 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00086216
- Testing
- Atiprimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Callisto Pharmaceuticals
Multiple Myeloma
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.
The purpose of this study is to measure the markers related to bone metabolism before and after the use of bortezomib injection in patients with multiple myeloma and to evaluate the effect bortezomib injection has on bone disease.
- Trial name
- NCT01026701
- Testing
- bortezomib
- Volunteers
- 104 people
- Sponsor
- Janssen Korea, Ltd., Korea
Myeloma, Multiple
CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma
This study is to determine the maximum tolerated dose(MTD) and recommened phase 2 dose(RP2D) based on dose limiting toxicity(DLT), and to evaluate safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in…
- Trial name
- NCT03150316
- Testing
- Treat Regimen
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Multiple Myeloma
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
This is a single-centre, single ascending dose (SAD) pilot study designed to evaluate the safety, tolerability, including local tolerability, and pharmacokinetics (PK) of NEX-20A (lenalidomide) after the administration of a…
- Trial name
- NCT05643248
- Testing
- NEX-20A
- Where
- Sweden
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Nanexa AB
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
The purpose of this study was to evaluate the safety and tolerance of BEBT-908 for injection in the treatment of recurrent refractory malignant lymphoma, multiple myeloma and chronic lymphoblastic leukemia, and to obtain the…
- Trial name
- NCT06082596
- Testing
- BEBT-908 for injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- BeBetter Med Inc
Anemia of Chronic Disease
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer
This study is conducted to determine the safety, tolerability, and efficacy of NOX-H94 in patients with anemia of chronic disease (ACD).
- Trial name
- NCT01691040
- Testing
- NOX-H94
- Where
- 11 sites in Austria, Bulgaria and 1 more
- Volunteers
- 12 people
- Sponsor
- TME Pharma AG
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with…
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer
- Trial name
- ARC-12 (NCT04772989)
- Testing
- AB308, Zimberelimab
- Where
- 22 sites in United States, Poland and 1 more
- Volunteers
- 94 people
- Sponsor
- Arcus Biosciences, Inc.
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04504825
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 125 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Myeloma
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
- Trial name
- NCT00423644
- Testing
- Darinaparson
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Alaunos Therapeutics
Multiple Myeloma
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma
This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely.
- Trial name
- NCT00547404
- Testing
- P276-00
- Volunteers
- 35 people
- Sponsor
- Piramal Enterprises Limited
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia
The clonoSEQ® Watch Registry
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
- Trial name
- NCT04545333
- Testing
- clonoSEQ Assay
- Where
- 14 sites in United States
- Volunteers
- 465 people
- Sponsor
- Adaptive Biotechnologies
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT00511238
- Testing
- carfilzomib
- Where
- 34 sites in United States, Canada
- Volunteers
- 312 people
- Sponsor
- Amgen
Multiple Myeloma
Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered to patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00594126
- Testing
- Imetelstat Sodium (GRN163L)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Geron Corporation
Multiple Myeloma
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe
With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data is available yet on how the drug is being used outside of the clinical trial setting.
- Trial name
- NCT03091127
- Where
- 114 sites in Austria, Belgium and 9 more
- Volunteers
- 705 people
- Sponsor
- Amgen
Multiple Myeloma
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Phase 1 is an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT02548962
- Testing
- Ibrutinib, Pomalidomide, Dexamethasone
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 11 people
- Sponsor
- Pharmacyclics LLC.
Multiple Myeloma
Dasatinib in Combination With Revlimid (and Dexamethasone)
The purpose of this study was to determine the safety and tolerability of dasatinib when given in combination with lenalidomide and a low dose dexamethasone for the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT00560391
- Testing
- Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg, Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.